ERBB2 mutation: A promising target in non-squamous cervical cancer.

CONCLUSIONS: This study provided a promising rationale for the clinical investigation of tyrosine kinase inhibitors for the treatment of cervical cancer with ERBB2 mutations. Patients with non-squamous cell carcinomas have priority as candidates for ERBB2-targeted therapy. Concurrent PIK3CA/RAS mutations should be considered in the design of clinical trials.
PMID: 29279289 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - December 23, 2017 Category: Cancer & Oncology Authors: Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G, Yang H Tags: Gynecol Oncol Source Type: research